

University of Groningen

Pharmaceutical compositions and methods for treating tuberculosis

van der Geize, Robert; Dijkhuizen, Lubbert; Ostendorf, Martin; van der Meijden, Peter

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:
2010

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

van der Geize, R., Dijkhuizen, L., Ostendorf, M., & van der Meijden, P. (2010). Pharmaceutical compositions and methods for treating tuberculosis. (Patent No. *WO2010094810*).

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.



(51) International Patent Classification:

A61P 31/04 (2006.01) *A61K 31/122* (2006.01)
A61P 31/06 (2006.01) *A61K 31/222* (2006.01)
A61K 31/045 (2006.01)

Borch 28, NL-9474 RB Zuidlaren (NL). **OSTENDORF, Martin** [NL/NL]; P.O. Box 20, NL-5340 BH Oss (NL).
VAN DER MEIJDEN, Peter [NL/NL]; P.O. Box 20, NL-5340 BH Oss (NL).

(21) International Application Number:

PCT/EP2010/052299

(74) Agent: **QUELLE-FONTIJN, Monique**; N.V. Organon, P.O. Box 20, NL-5340 BH Oss (NL).

(22) International Filing Date:

23 February 2010 (23.02.2010)

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

09153466.9 23 February 2009 (23.02.2009) EP

(71) Applicant (*for all designated States except US*): **N.V. ORGANON** [NL/NL]; Kloosterstraat 6, NL-5349AB Oss (NL).


(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **VAN DER GEIZE, Robert** [NL/NL]; Zaagmuldersweg 586, NL-9713 LZ Groningen (NL). **DIJKHUIZEN, Lubbert** [NL/NL]; Ter


(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,

[Continued on next page]


(54) Title: PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS




Compound I



(+) -Compound II



(-) -Compound II



Compound III

(57) Abstract: A pharmaceutical composition for the treatment of a disease caused by a bacterium that belongs to the group of nocardioform actinomycetes, said composition comprising an effective amount of a compound selected from compound I, (+)-compound II, (-)- compound II, compound III, or mixtures thereof.



TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS

FIELD OF INVENTION

5 The present invention pertains to a pharmaceutical composition for use in the treatment of a disease caused by a bacterium that belongs to the group of nocardioform actinomycetes. Furthermore, the invention also pertains to a method for treating a subject suffering from a disease caused by a bacterium that belongs to the group of nocardioform actinomycetes. Finally, the invention provides a new compound.

10

BACKGROUND OF THE INVENTION

Within the class Actinobacteria there is an order of bacteria called Actinomycetales, commonly referred to as actinomycetes. Bacteria that belong to this order are filamentous gram positive bacteria (several species however have complex cell wall
15 structures which makes classic Gram staining less- or even unsuitable, for example as is the case with many species that belong to the Actinomycetales family Mycobacteriaceae) with a high G+C content. They are best known as soil dwelling organisms, although various strains inhabit plants and animals, including humans. They produce resistant spores which are often attached to aerial mycelium or hyphae.
20 Actinomycetes play an important role in the decomposition of organic material. Several species are used in industry and pharma-research because of their typical properties.

Most actinomycetes are non-pathogenic for animals, including humans. However, within the many suborders of the actinomycetes (i.a. Streptosporangineae,
25 Micrococcineae, Streptomycineae and Frankineae) there is one suborder, viz. the Corynebacterineae, which houses, next to a large amount of non-pathogenic bacteria, a substantial number of pathogens. It appears that these pathogens reside within the phylogenetic group known as the nocardioform actinomycetes, which encompasses the families Mycobacteriaceae, Nocardiaceae and Corynebacteriaceae (see i.a. chapter 11,
30 titled: *Rhodococcus equi*: Pathogenesis and Replication in Macrophages, in "Opportunistic Intracellular Bacteria and Immunity", by Lois J. Paradise et al (eds.), New York, 1999).

During recent years the recognition that the families Mycobacteriaceae, Nocardiaceae
35 and Corynebacteriaceae of the phylogenetic group of nocardioform actinomycetes are

very closely related families within the suborder of the Corynebacterineae, has been confirmed (see also University of California, San Diego, Outline of Senior Project, Marelle L. Yehuda, June 2, 2005). It has also become clear that in particular the pathogenic bacteria in this group, at least the ones for which no adequate prophylactic treatment is available (such as for example *Mycobacterium tuberculosis*, *Nocardia seriolae* and *Rhodococcus equi*), have an important property in common: infection typically occurs via skin or mucous membrane, followed by dissemination of the bacteria within macrophages and replication within these macrophages (see i.a. Microbes and Infection 7, 2005, 1352-1363; Proceedings of the National Academy of Sciences, June 7, 2005, Vol. 102, no 23, pp 8327 – 8332; Nature Medicine 13, 282 – 284, 2007; Transplantation Proceedings, Volume 36, Issue 5, June 2004, pp 1415 – 1418). Indeed macrophages are at the frontline of host immune defense against microbial infections, but unlike bacteria that depend on the avoidance of phagocytosis to survive in the host, the currently contemplated pathogenic bacteria within this group target macrophages to survive and even replicate in the host. The present invention is concerned with these bacteria that have the ability to survive within macrophages of a human or animal, and in connection with the current invention will be referred to as macrophage surviving nocardioform actinomycetes.

Apparently, the macrophage surviving nocardioform actinomycetes have evolved to evade critical functions of a human defense against microbes. In particular *Mycobacterium tuberculosis*, the causative microbe of tuberculosis, is a species that has successfully exploited macrophages as its primary niche in vivo, but other bacterial species that belong to the group of nocardioform actinomycetes, including Mycobacteriaceae, Nocardiaceae and Corynebacteriaceae, have adopted the same strategy. These are for example *Mycobacterium ulcerans* that causes Buruli ulcer, *Mycobacterium avium paratuberculosis* that causes Johne's disease in cattle and which is linked to Crohn's disease in humans, *Mycobacterium bovis* that causes bovine tuberculosis, *Mycobacterium avium* which is related to opportunistic infection of immunocompromised subjects such as AIDS-patients, *Nocardia seriolae* and *Nocardia farcinia* that cause nocardiosis in fish, *Nocardia asteroides* which causes infection in renal transplant recipients, *Rhodococcus equi* (formerly known as *Corynebacterium*) that causes pneumonia in foals and which is also connected to opportunistic infections in immunocompromised subjects, *Corynebacterium pseudotuberculosis* that causes

abscesses, i.a. in the lungs, in sheep, goats, horses and occasionally also in humans, etc. All of these bacterial species have in common the ability to survive within macrophages, infect them and replicate within this type of host cell.


- 5 This typical property seriously hampers the treatment for disorders (in this specification the term “disorder” is used as an equivalent for “disease”) arising from an infection with a bacterium that belongs to the group of macrophage surviving nocardioform actinomycetes. In particular, tuberculosis caused by infection with *Mycobacterium tuberculosis* is a leading cause of mortality from bacterial infection, latently infecting a
- 10 third of the world's population and killing 2-3 million people each year. After years in decline, *Mycobacterium tuberculosis* infections are increasing, largely due to two lethal developments: the association of tuberculosis with HIV-infected individuals and the emergence of multidrug- resistant (MDR) strains of *Mycobacterium tuberculosis*.
- 15 The current standard chemotherapy for tuberculosis involves a 6-month treatment program and a cocktail of drugs: an initial 2-month treatment with 4 drugs (isoniazid (INH), rifampin (RIF), pyrazinamide, and ethambutol) followed by an additional 4-month treatment with INH and RIF. The inadequacies of this chemotherapy include its toxicity, poor patient compliance with the lengthy treatment, and ineffectiveness against MDR
- 20 strains. Chemotherapy against MDR – *Mycobacterium tuberculosis* involves more toxic drugs, may last up to two years and is expensive with the additional complication of even poorer patient compliance.

Accordingly, a long felt need exists for safe and effective methods for treatment of


25 tuberculosis and other diseases caused by a bacterium that belongs to the group of nocardioform actinomycetes and providing pharmaceutical compositions for the treatment of a disease caused by a bacterium that belongs to the group of nocardioform actinomycetes.

SUMMARY OF THE INVENTION


The present invention provides in a first embodiment a pharmaceutical composition for use in the treatment of a disease caused by a bacterium that belongs to the group of nocardioform actinomycetes, said composition comprising an effective amount of a compound selected from compound I, (+)-compound II, (-)-compound II, compound III, or mixtures thereof:




Compound I



(+) -Compound II



(-) -Compound II




Compound III

10

In a second embodiment the present invention provides a method for treating a subject suffering from a disease caused by a bacterium which belongs to the group of nocardioform actinomycetes, said method comprising administering to the subject an effective amount of a compound selected from compound I, (+)-compound II, (-)-compound II, compound III, or mixtures thereof.

15

Finally, the present invention provides a novel compound (+)-(1S, 3aR, 7aS)-7a-methyl-1H-octahydroinden-1-ol



(+)-Compound II

5

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 illustrates growth of gene inactivated mutants of *R. erythropolis* RG8-37 on glucose mineral agar medium supplemented with 0.01% (w/v) HIL. No growth indicates the formation of the growth inhibitor, whereas growth indicates that the introduced gene inactivation blocked inhibitor synthesis. Gene inactivation of *fadD3* (strain RG47), *ipdF* (strain RG48) and *fadE30* (strain RG8-37/pAR1818) in strain RG8-37, but not *fadE31* (strain RG45) and *echA13* (strain RG46), releases growth inhibition caused by the presence of HIL. This indicates that HIL is further metabolized into a toxic compound which involves at least *fadD3*, *ipdF* and *fadE30* in strain RG8-37.

Figure 2 illustrates chemical structures of test compounds used.

Figure 3A illustrates growth curves of wild type strain *Rhodococcus erythropolis* SQ1 on glucose mineral medium in the absence (diamonds) and presence of 0.01% of (-)-compound II (stars), 0.01% of compound III (circles), 0.01% of racemic compound II (squares), or 0.01% of (+)-compound II (triangles)..

Figure 3B illustrates growth curves of wild type strain *Mycobacterium smegmatis* mc²155 on glucose mineral medium in the absence (diamonds) and presence of 0.01% of racemic compound II (squares) or compound III (circles).

DETAILED DESCRIPTION OF THE INVENTION

It has been described in literature that cholesterol metabolism plays a crucial role in the survival of nocardioform actinomycetes in macrophages and is an important virulence factor (Proceedings of the National Academy of Science, February 6, 2007, vol. 104, no. 6, pp 1947-1952).

Various genes of *Mycobacterium tuberculosis* involved in cholesterol catabolism are specifically expressed during growth in macrophages (SCHNAPPINGER et al 2003. J. Exp Med 198:693-704) and a subset of these genes are essential for survival in macrophages (RENGARAJAN et al 2005. Proc. Natl. Acad. Sci USA 102:8327- 32).

Several genes have been implicated in preventing acidification of the *Mycobacterium tuberculosis*-containing phagosome (PETHE et al 2004. Proc. Natl. Acad. Sci USA 101:13642-13647).

Macrophage plasma membrane cholesterol has a role in internalization of mycobacteria by macrophages, and sequestration of cholesterol in an in vitro macrophage model inhibits uptake and phagocytosis of mycobacterial. (GATFIELD et al 2000. Science 288: 1647-1 650; PEYRON et al 2001. J. Immunol 165:5186-5191).

Catabolic studies in a mycobacterial strain indicated that cholesterol is degraded via 4-androstene-3, 17-dione (4-AD) with side chain degradation at C-17 likely preceding steroid ring degradation (SMITH et al 1993. Appl. Environ. Microbiol. 59:1425-1429).

It has also been suggested that cholesterol catabolism provides logical targets for novel therapeutic agents to combat disease causing strains, i.e. drugs for treatment after infection has occurred. Indeed, when applying hindsight there is other supporting evidence for the established fact that for all macrophage surviving nocardioform actinomycetes, cholesterol catabolism plays a role in the survival and persistence of the bacteria in host macrophages. For example, from chapter 11 (titled: *Rhodococcus equi*: Pathogenesis and Replication in Macrophages) in "Opportunistic Intracellular Bacteria and Immunity", by Lois J. Paradise et al (eds.), New York, 1999) it is known that there are great similarities in the clinical symptomatology between infections caused by several nocardioform actinomycetes and cholesterol oxidase was determined to be an enzymatic component of virulence factors. In Veterinary Microbiology, Volume 56, Issue


3-4, June 1997, 269-276 it is shown that *Corynebacterium pseudotuberculosis* is involved in the cholesterol oxidase process together with *Rhodococcus equi*.

WO 2007/118329 discloses enzymes involved in cholesterol degradation in *Mycobacterium tuberculosis*. Some of these enzymes are essential for growth of *Mycobacterium tuberculosis* in the macrophage and participate in oxygenolytic cleavage of the rings of cholesterol. Described are substrate analogues and inhibitors of such enzymes which may be used for the treatment of mycobacterial infections including tuberculosis.


As is commonly known, methylhexahydroindanedione propionate (HIP; 3 α -H-4 α -(3'-propionic acid)-7 α β -methylhexahydro-1,5-indanedione) and 5-hydroxy-methylhexahydroindanone propionate (HIL; 3 α -H-4 α -(3'-propionic acid)-5 α -hydroxy-7 α β -methylhexahydro-1-indanone- δ -lactone) are formed during the degradation of cholesterol by actinobacteria, including the macrophage surviving nocardioform actinomycetes. Recently, an operon (called *ipdAB*: indanedione propionate degradation Alfa + Beta) has been identified in bacterial species that belong to the suborder of Corynebacterineae. This *ipdAB* operon encodes the α and β subunit of a transferase that is involved in HIP and HIL degradation (see co-pending International Patent application PCT/EP2008/060844, filed 19 August 2008, based on a US priority application filed 21 August 2007). Inactivation of the *ipdAB* genes in *Rhodococcus*, encoding *ipdAB*, has shown to have marked inhibitory effects and effectively blocks cholesterol metabolism and 9 α -hydroxylation of 4-androstene-3,17-dione (AD).

Based on these results it was stipulated that HIP or HIL or metabolites derived thereof might inhibit growth of *Rhodococcus* indicating the formation from these two compounds of a natural growth inhibitor acting as an antibiotic.


Surprisingly, it was found that the compounds I, (+)-II, (-)-II, and III




Compound I



(+)-Compound II




(-)-Compound II



Compound III

- 5 show inhibitory activity in wild type *Rhodococcus erythropolis* SQ1.

In particular (+)-compound II resulted in the most effective growth inhibition.




(+)-Compound II

- 10 *lpdAB* homologous genes are present in other nocardioform actinomycetes, including *M. tuberculosis*. As mentioned above, it was reported by others in the literature that knocking out certain genes in *M. tuberculosis* resulted in its inability to survive in macrophages and it was concluded that these might be pathogenicity genes (RENGARAJAN et al 2005. Proc. Natl. Acad. Sci USA 102:8327- 32). The function of


these genes in *M. tuberculosis* was not clear to RENGARAJAN et al., but the present inventors were able to recognize that they have a sequence similar to that of *ipdAB* (called rv3551 and rv3552 genes, respectively).

- 5 Accordingly, the present invention provides in a first embodiment a pharmaceutical composition for use in the treatment of a disease caused by a bacterium that belongs to the group of nocardioform actinomycetes, said composition comprising an effective amount of a compound selected from compound I, (+)-compound II, (-)-compound II, compound III, or mixtures thereof:


10




Compound I



(+) -Compound II



(-) -Compound II




Compound III

- 15 In a second embodiment the present invention provides a method for treating a subject suffering from a disease caused by a bacterium which belongs to the group of nocardioform actinomycetes, said method comprising administering to the subject an effective amount of a compound selected from compound I, (+)-compound II, (-)-compound II, compound III, or mixtures thereof.

Alternatively, the disease is caused by a bacterium of one of the family Mycobacteriaceae, Nocardiaceae or Corynebacteriaceae. More preferably, the disease is caused by a bacterium of one of the genera *Mycobacterium*, *Nocardia*, *Rhodococcus*, and *Corynebacterium*. Most preferably, the disease is caused by a bacterium of one of the species *Mycobacterium tuberculosis*, *Mycobacterium ulcerans*, *Mycobacterium bovis*, *Mycobacterium avium*, *Mycobacterium avium paratuberculosis*, *Nocardia seriolae*, *Nocardia farcinia*, *Nocardia asteroides*, *Rhodococcus equi*, or *Corynebacterium pseudotuberculosis*.

- 10 In an alternative embodiment, diphtheria, tuberculosis in cattle, equine tuberculosis, or tuberculosis in humans are diseases which can be treated by the pharmaceutical compositions of the present invention.


Preferably, the pharmaceutical composition comprises (+)-compound II



(+)-Compound II

Racemic compound I and its preparation is known i.a. from Snider B. et al, J. Am. Chem Soc., 1983, 105, 2364-2368.

Racemic compound II has been published by Müller, M. et al, Tetrahedron, 1981, 37, 257. Racemic compound II can be prepared by reduction of racemic compound I under the influence of sodiumborohydride in ethanol.




racemic compound I

racemic compound II

For racemic compound II, the following nomenclature is suggested: rac-(1 β ,3 α ,7 $\alpha\beta$)-7a-methyl-1H-octahydroinden-1-ol.


The (+)- and (-)-enantiomers of compound II are novel compounds. They can be obtained by separation of the racemic mixture via preparative chiral HPLC of the corresponding *o*-nitrobenzoate ester (rac-4).



After isolation of the individual enantiomers, the ester groups are saponified under the influence of aqueous sodium hydroxide in ethanol. In this manner, the enantiomers of compound II can be obtained in pure form (enantiomeric excess >95%).

15

The absolute configuration of both enantiomers of compound II was determined by ^1H -NMR and ^{13}C -NMR studies, following the methoxyphenylacetic (MPA) ester-approach as described by Latypoc, Sh.K. et al, J. Org. Chem., 1996, 61, 8569. The (-)-enantiomer of compound II was transformed into the corresponding methoxyphenylacetic esters 5, using both (S)-MPA and (R)-MPA. The absolute configuration of the (-)-enantiomer was determined to be (1R, 3aS, 7aR).



- 10 (-)-(1R, 3aS, 7aR) 7a-methyl-1H-octahydroinden-1-ol is the less active enantiomer.
 (+)-(1S, 3aR, 7aS)-7a-methyl-1H-octahydroinden-1-ol corresponds to the active enantiomer.

Compound III and its preparation is known i.a. from Takeda K. et al., Chem. Pharm. Bull., 23 (11), 1975, pp. 2711-2727.

As used herein, a "subject" refers to a human or other animal.

Compounds of the invention can be provided alone or in combination with other compounds (for example, nucleic acid molecules, small molecules, peptides, or peptide analogues), in the presence of a liposome, an adjuvant, or any pharmaceutically acceptable carrier, in a form suitable for administration to mammals, for example, humans, cattle, sheep, horses, etc. If desired, treatment with a compound according to the invention may be combined with more traditional and existing therapies for a disease caused by a bacterium that belongs to the group of nocardioform

actinomycetes, e.g., tuberculosis. For example, treatment with one or more of compound I, (+)-compound II, (-)-compound II, or compound III may be combined with one or more of isoniazid (INH), rifampin (RIF), pyrazinamide or ethambutol.

- 5 Compositions comprising one or more of compound I, (+)-compound II, (-)-compound II, or compound III according to any of the various embodiments of the invention, may be administered as a dose from about 0.1 ug/kg to about 20 mg/kg (based on the mass of the subject), or any amount there between, for example from about 1ug to about 2000 ug/ml or any amount there between, about 10 ug to about 1000 ug or any amount there
10 between, or about 30ug to about 1000 ug or any amount there between. For example, a dose of about 0.1, 0.5, 1.0, 2.0, 5.0, 10.0 15.0, 20.0, 25.0, 30.0, 35.0, 40.0, 50.0 60.0, 70.0, 80.0, 90.0, 100, 120, 140, 160 180, 200, 250, 500, 750, 1000, 1500, 2000, 5000, 10000, 20000 ug, or any amount there between may be used. In alternative embodiments, a suitable dosage range may be any integer from 0.1 nM-0.1 M, 0.1 nM-
15 0.05M, 0.05 nM-1 5μM or 0.01 nM-10 μM.

An "effective amount" of a compound as used herein refers to the amount of compound required to have a prophylactic, palliative or therapeutic effect when administered to a subject. For therapeutic or prophylactic compositions, the compounds may be
20 administered to an individual in an amount sufficient to stop or slow a disease caused by a bacterium that belongs to the group of nocardioform actinomycetes, e.g., tuberculosis. A "therapeutically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result, such as elimination or reduction in the severity of a disease caused by a bacterium that
25 belongs to the group of nocardioform actinomycetes, e.g. tuberculosis. A therapeutically effective amount of a compound may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the compound to elicit a desired response in the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response. A therapeutically effective amount is also one in which
30 any toxic or detrimental effects of the compound are outweighed by the therapeutically beneficial effects. A "prophylactically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result, such as prevention of a disease caused by a bacterium that belongs to the group of nocardioform actinomycetes, e.g. tuberculosis. Typically, a prophylactic dose is used in

subjects prior to or at an earlier stage of disease, so that a prophylactically effective amount may be less than a therapeutically effective amount.

Mixed with pharmaceutically suitable carriers, e.g. as described in the standard reference, Gennaro et al., Remington's Pharmaceutical Sciences, (18th ed., Mack Publishing Company, 1990, see especially Part 8: Pharmaceutical Preparations and Their Manufacture) the compounds may be compressed into solid dosage units, such as pills, tablets, or be processed into capsules or suppositories. By means of pharmaceutically suitable liquids the compounds can also be applied in the form of a solution, suspension, emulsion, e.g. for use as an injection preparation, or as a spray. For making dosage units, e.g. tablets, the use of conventional additives such as fillers, colorants, polymeric binders and the like is contemplated. In general any pharmaceutically acceptable carrier which does not interfere with the function of the active compounds can be used. Suitable carriers with which the compositions can be administered include lactose, starch, cellulose derivatives and the like, or mixtures thereof, used in suitable amounts. Thus, compositions of the invention can be formulated for any route of administration.

The invention will be further explained using the following examples describing specific embodiments of the present invention.

EXPERIMENTAL PROCEDURES

Culture media and growth conditions

Rhodococcus erythropolis SQ1 wild type and mutant strains were grown at 30°C (200 rpm) in LBP medium consisting of 1% Bacto-Peptone (BD), 0.5% Yeast Extract (BD) and 1% NaCl (Merck). *Mycobacterium smegmatis* mc²155 wild type and mutant strains (Snapper *et al.*, 1990, *Mol. Microbiol.* 4:1911-1919) was grown at 37°C (200 rpm) in BBL trypticase soy broth (TSB; BD) supplemented with 0.05% Tween80. Mineral medium (MM, pH 7.2) contained K₂HPO₄ (4.65 g/l), NaH₂PO₄·H₂O (1.5 g/l), Na-acetate (2 g/l), NH₄Cl (3 g/l), MgSO₄·7H₂O (1 g/l), and Vishniac stock solution (1 ml/l). MM medium was supplemented with different carbon and energy sources: glucose (20 mM), glycerol (20 mM), AD (0.5 g/l), or HIL (0.5 g/l). Vishniac stock solution was prepared as follows (modified from Vishniac and Santer (1957) *Bacteriol Rev* 21: 195–213): EDTA (10 g/l) and ZnSO₄·7H₂O (4.4 g/l) were dissolved in distilled water (pH 8 using 2 M KOH). Then, CaCl₂·2 H₂O (1.47 g/l), MnCl₂·7 H₂O (1 g/l), FeSO₄·7 H₂O (1 g/l), (NH₄)₆ Mo₇O₂₄·4 H₂O (0.22 g/l), CuSO₄·5 H₂O (0.315 g/l) and CoCl₂·6 H₂O (0.32 g/l) were added in that order at pH 6 and finally stored at pH 4. For growth on solid media Bacto-agar (15 g/l; BD) was added. HIL stock solutions (100 mg/ml) were prepared in 1 M NaOH.

AD bioconversion

Pre-cultures of *R. erythropolis* RG8-37 parent and mutant strains were grown in 25 ml LBP medium for 24-36 hours at 30°C and used to inoculate 50 ml liquid glucose mineral medium (1:100). The cultures were grown for 40 hours at 30°C at which point AD (0.5 g/l) and HIL (100 mg/l) were added. The bioconversion of AD into 9OHAD was followed by sampling every 2 hours. Steroid content of the samples was analyzed by high-performance liquid chromatography (HPLC). Culture samples (0.5 ml) were mixed with 2 ml of 80% methanol solution and filtered (0.2 µm) prior to analysis by HPLC-UV_{254nm}. HPLC was performed on a C18 column (250 x 4.6 mm; Alltech, Deerfield, USA, 35°C) using a mobile phase consisting of methanol:water (80:20) at a flow rate of 1 ml/min. Percentage of AD conversion was calculated as (9OHAD peak area/ AD peak area)/ (9OHAD peak area + AD peak area) *100%.

Growth inhibition screening-assays *R. erythropolis* and *M. smegmatis*

Inhibition of growth of *R. erythropolis* strains was tested on glucose mineral agar plates. Growth inhibition of *R. erythropolis* strains and *M. smegmatis* strains was also tested in glucose or glycerol mineral liquid media containing the test compound at a final concentration of 100 mg/l. Pre-cultures (25 ml) of *R. erythropolis* strains and *M. smegmatis* strains were grown in LBP or TSB + 0.05% Tween80, respectively, for 24-36 hours and used to inoculate (1:100) MM medium (50 ml) supplemented with glucose (20 mM) or glycerol (20 mM). Test compounds were added to the medium prior to inoculation in a final concentration of 100 mg/L from stock solutions (100 g/L) dissolved in 1 M NaOH (HIL) or methanol (all other compounds tested). Cell growth was followed by measuring cell culture turbidity at 600 nm for several days.

Gene inactivation of *fadD3*, *echA13*, *fadE31* and *ipdF* in *R. erythropolis* RG8-37

Unmarked gene deletion mutant strains of strain RG8-37 were essentially constructed using the *sacB* counter selection method as reported previously (van der Geize *et al.* (2001) *FEMS Microbiol Lett* 205:197-202). Gene disruption was essentially performed as described (Van der Geize *et al.* (2000) *Appl Environ Microbiol* 66: 2029-2036). In order to delete *fadE31*, plasmid pAR1812 was constructed as follows. Plasmid pAR1800 was digested with *Scal*/*Bgl*III, treated with Klenow and self-ligated, resulting in pAR1811. Subsequently, pAR1811 was cut with *Sph*I/*Hind*III and treated with Klenow, and a 3.2 kb DNA fragment carrying a 0.4 kb deletion in *fadE31* was ligated into *Sph*I/*Hind*III digested pK18mobsacB, yielding pAR1812. *R. erythropolis* mutant strain RG45 was subsequently made using pAR1812 carrying a *fadE31* gene deletion. The *fadE31* deletion was confirmed by PCR using forward primer 5' ACGCCACAACCGCATTCCGTGA and reverse primer 5' TCGTTGGTGCCTGCGTAGATCG resulting in a 685 bp product for the *fadE31* mutant as compared to 1,085 bp for the wild type gene. For *echA13* gene deletion, plasmid pAR1816 was constructed as follows. A 2.9 kb *Acc*65I DNA fragment was treated with T4 DNA polymerase and blunt ligated into *Sma*I digested pK18mobsacB. The resulting plasmid, pAR1815, was subsequently digested with *Bst*XI, treated with T4 DNA polymerase and self ligated, yielding pAR1816 carrying a 0.45 kb deletion of *echA13*. *R. erythropolis* mutant strain RG46 was subsequently made using pAR1816 carrying an *echA13* gene deletion. The *echA13* deletion was confirmed by PCR using forward primer 5' GCAGGCAACGGACCTCACTTCA and reverse primer 5'

CTAGTTTGTTCCTTCCTGCGGT resulting in a 239 bp product for the *echA13* mutant as compared to 699 bp for the wild type gene. For *fadD3* deletion, plasmid pAR1817 was constructed as follows. A 3.7 kb *SpeI* DNA fragment of pAR1800 carrying *fadD3* was ligated into pBluescript (II) KS, yielding pAR1813. A 0.8 kb internal DNA fragment of *fadD3* was removed by *SgrAI* restriction of pAR1813 followed by self-ligation. The resulting plasmid pAR1814 was digested with *SpeI* and a 3 kb DNA fragment was ligated into *XbaI* digested pK18mobsacB, yielding pAR1817. *R. erythropolis* mutant strain RG47 was subsequently made using pAR1817 carrying a *fadD3* gene deletion. The *fadD3* deletion was confirmed by PCR using forward primer 5' CCGACTGACCTTCGCACAGCTA and reverse primer 5' ATGCCGATGGCAGCAGACTCGT resulting in a 489 bp product for the *fadD3* mutant as compared to 1,248 bp for the wild type gene.

For *fadE30* gene disruption, pAR1818 was constructed by ligating a Klenow treated 0.64 kb *BamHI/XmnI* blunt-end DNA fragment of pAR1800, harbouring an internal gene fragment of *fadE30*, into *SmaI* digested pK18mobsacB. The *R. erythropolis fadE30* disruption mutant strain RG8-37/pAR1818 was subsequently made by introduction of pAR1818 into strain RG8-37.

Construction of *Mycobacterium smegmatis* Δ ipdAB

For construction of the Δ ipdAB mutant of *M. smegmatis* strain mc²155, the non-replicative plasmid pK18-ipdABsmeg was mobilized to *M. smegmatis* by electrotransformation essentially as described (Jacobs *et al.* (1991) *Methods Enzymol* 204: 537-555). Briefly, cell cultures (250 ml) were grown at 37°C in TSB medium + 0.05% Tween80 until OD₆₀₀ reached 0.8, put on ice for one and a half hour and centrifuged (10 min at 5,000 x g) to pellet the cells. Cell pellets were washed twice with distilled water and resuspended in a final volume of 1 ml 10% glycerol and divided into 200 µl aliquots. MilliQ-eluted plasmid DNA (5-10 µl; GenElute Plasmid Miniprep Kit, Sigma-Aldrich) was added to 200 µl cells in 2 mm gapped cuvettes. Electroporation was performed with a single pulse of 12.5 kV/cm, 1000Ω and 25 µF. Electroporated cells were gently mixed with 1 ml TSB + 0.05% Tween80 and allowed to recover for 5 h at 37°C and 200 rpm. Aliquots (200 µl) of the recovered cells were plated onto selective TSB + 0.05% Tween80 agar containing kanamycin (10 µl/ml). Several transformants were obtained after 4-5 days of incubation at 37°C. One kanamycin resistant transformant was grown for 2 days at 37°C non-selectively in TSB medium containing

0.05% Tween80 and subsequently plated onto TSB agar plates containing 2% sucrose to select for kanamycin sensitive (Km^S) and sucrose resistant (Suc^R) double-recombinants by *sacB* counter-selection. Colonies appearing after 3 days of incubation were replica streaked onto TSB agar and TSB agar supplemented with kanamycin (10 μ l/ml) to select for Km^S/Suc^R colonies. Genuine Km^S/Suc^R colonies were further checked by colony PCR for the presence of the *ipdAB* gene deletion with forward primer *ipdABMsmegcont-F* ACGCCAGCTACCGCATGGAA and reverse primer *ipdABMsmegcont-R* ATCACCTCGCGCAGCAGCTT. Genomic DNA was isolated from three potential *ipdAB* mutants and PCR analysis using the aforementioned primers confirmed the presence of the *ipdAB* gene deletion (273 bp) and the absence of the wild type *ipdAB* genes (1697 bp) in all three mutants. One *ipdAB* mutant strain was chosen for further work and designated *M. smegmatis* $\Delta ipdAB$.

Synthesis of the (+)- and (-)-enantiomers of compound II

Synthesis of racemic 4

Racemic compound II (200 mg, 1.30 mmol) was reacted with *o*-nitrobenzoyl chloride (481 mg, 2.59 mmol), pyridine (210 μ l, 2.59 mmol) and DMAP (15.8 mg, 0.13 mmol) in dichloromethane. After stirring for 17 h at ambient temperature, the reaction was quenched with 1 M HCl and the product was extracted with ethyl acetate. The combined organic layers were washed with 1 M HCl, aqueous saturated $NaHCO_3$ solution and brine. The organic layer was dried with Na_2SO_4 and concentrated in vacuo. The crude material was purified by flash chromatography, yielding 300 mg of racemic ester 4 (74% yield).

Separation of enantiomers

The ester synthesis was repeated on a scale of 2.2 g. The thus obtained racemic ester was separated using a Chiralcel AD-H column (conditions 1% 2-propanol in heptane, flow 18 mL/min, 30 min, collected at $\lambda=210$ nm, collection threshold 10 mV). The two enantiomers were obtained in 0.65 g and 0.55 g respectively (see Table).

(-)-4	(+)-4
0.65 g	0.55 g
Purity (GC) >95%, ee >95% (chiral HPLC)	Purity (GC) >95%, ee >95% (chiral HPLC)
$[\alpha]_D^{20} = -36.2$ (c =1, CHCl ₃)	$[\alpha]_D^{20} = +41.3$ (c =1, CHCl ₃)

Removal of the benzoate esters

Both enantiomers were subjected to the same saponification methods. A suspension of
 5 appr. 600 mg of the ester in 12 mL ethanol was treated with 10% aqueous NaOH (3 mL). The reaction was continued at room temperature and the conversion was monitored by LC/MS. After full conversion, the product was extracted with ethyl acetate. After washing, drying and concentration, the product was obtained (appr. 200 mg).

(-)-compound II	(+)-compound II
244 mg	187 mg
Purity (GC/MS) >95%	Purity (GC/MS) >95%
$[\alpha]_D^{20} = -18.5$ (c =1, CHCl ₃)	$[\alpha]_D^{20} = +14.0$ (c =1, CHCl ₃)

10

Formation of the MPA esters

To determine the absolute configuration via NMR studies, the (-)-enantiomer of compound II was transformed into the corresponding methoxyphenylacetic (MPA) ester. For the NMR studies both diastereomers of ester 5 were formed from (S)- and (R)-MPA
 15 respectively. To this end, MPA (166 mg, 1.0 mmol) was reacted with oxalyl chloride (0.26 mL, 3.0 mmol) in THF (2 mL) in the presence of a catalytic amount of DMF. After stirring for 2 h at ambient temperature, the reaction mixture was concentrated in vacuo. The thus obtained acid chloride of MPA was dissolved in pyridine and a solution of (-)-
 20 compound II (30 mg, 0.19 mmol) in pyridine (1 mL) and a catalytic amount of DMAP were added. After stirring for 17 h at ambient temperature, the reaction mixture was quenched with a citric acid solution. The product was extracted with ethyl acetate. The residue obtained after concentration of the combined organic layers was purified by column chromatography. The product was obtained as a white foam (30 mg, 0.099 mmol, 52% yield). The absolute configuration of the (-)-enantiomer was determined to

be (1R, 3aS, 7aR) via NMR studies. Thus, the absolute configuration of the (+)-enantiomer is (1S, 3aR, 7aS).

5 EXAMPLES

Metabolism of AD is necessary for inhibitor formation: construction of ipdAB gene deletion mutant R. erythropolis RG8-37 to uncouple steroid degradation from inhibitor formation

10 To confirm that the inhibitor is formed through AD metabolism in an *ipdAB* mutant genetic background, an *ipdAB* gene deletion was made in a *R. erythropolis* mutant strain (strain RG8) that cannot completely metabolize AD. *R. erythropolis* strain RG8 is a mutant strain devoid of the 3-ketosteroid $\Delta 1$ dehydrogenase (KSTD), encoding genes *kstD* and *kstD2*. Strain RG8 is effectively blocked in AD $\Delta 1$ -dehydrogenation and
15 capable of stoichiometric conversion of AD into 9OHAD due to 3-ketosteroid 9 α -hydroxylase activity (WO2001/031050; Van der Geize *et al.* (2002) *Mol Microbiol* 45: 1007-1018). 9OHAD cannot be converted further to lower pathway intermediates due to the absence of KSTD activity. Unmarked in-frame gene deletion of *ipdA* and *ipdB* in *R. erythropolis* strain RG8 was achieved using plasmid pAR31 as described previously
20 (co-pending International Patent application PCT/EP2008/060844, filed 19 August 2008). The resulting *ipdAB kstD kstD2* mutant strain of *R. erythropolis* RG8 was designated strain RG8-37. Mutant strain RG8-37 did not grow on MM agar plates supplemented with HIL (MM-HIL) as sole carbon and energy source.

Bioconversion of AD (0.5 g/L) with cell cultures of strain RG8-37 grown in mineral
25 glucose medium revealed that 3-ketosteroid 9 α -hydroxylase (KSH) activity was not inhibited: *R. erythropolis* strain RG8-37 performed AD conversions into 9OHAD with yields of up to 90% within 8 hours. These results indicated that the inhibitor of KSH activity is formed following the degradation of AD in an *ipdAB* mutant.

Addition of HIL (100 mg/L) to similar AD bioconversions by cell cultures of strain RG8-
30 37 resulted in a marked inhibition of AD 9 α -hydroxylation (20% conversion in 8 hours), indicating that the inhibitor is either HIL or a metabolite thereof.

***ipdAB* gene inactivation results in HIL-dependent growth inhibition on glucose**

In order to examine the effects of HIL on normal cell growth of *R. erythropolis* strain RG8-37, it was streaked onto glucose mineral agar medium (control) and glucose mineral agar medium supplemented with HIL (0.01% w/v). Strain RG8-37 cells plated
5 onto glucose mineral medium without HIL grew normally, whereas no growth of RG8-37 was observed on glucose agar plates containing HIL after 3 days of incubation. These results indicate that HIL, or a metabolite thereof, has antibiotic properties towards *R. erythropolis* RG8-37 inhibiting normal cell growth.

Cell cultures of strain RG8-37, inoculated into liquid glucose mineral media containing
10 HIL (100 mg/l), were unable to grow over a period of 96 hours, whereas wild type strain SQ1 grew to stationary phase within 72 hours under the same conditions. This growth experiment was used in subsequent work as an inhibition screening assay to identify compounds and genes involved in formation of the inhibitor.

Identification of additional genes of R. erythropolis involved in HIL metabolism

HIL and its metabolism play an important role in the formation of the inhibitor. To identify additional genes involved in HIL degradation, UV mutant strain AP18 blocked in growth on MM medium supplemented with HIL was isolated from UV mutagenic treatment of *R. erythropolis* SQ1 as described previously (co-pending International
20 Patent application PCT/EP2008/060844, filed 19 August 2008). HIL growth deficient mutants (HIL⁻) of *R. erythropolis* SQ1, growing well on mineral glucose (20 mM) agar plates, were selected following UV mutagenesis. One UV mutant strain, designated AP18, had a glucose⁺/HIL⁻ growth phenotype and was selected for further work. Functional complementation of the mutant HIL⁻ growth phenotype was performed by
25 introducing a genomic library of *R. erythropolis* (Van der Geize *et al.* (2002) *Mol Microbiol* 45:1007-1018) into mutant strain AP18. Colonies that regained the capability to grow on mineral agar medium supplemented with HIL were picked and used for plasmid DNA extraction, resulting in the isolation of plasmid pAR1800. Nucleotide sequence analysis of pAR1800 revealed a total number of 5 intact genes. Thus, one or
30 several of these genes are involved in growth on HIL as sole carbon and energy source. Database similarity searches indicated that these genes were likely functional homologues of *fadD3* (*rv3561*), *fadE30* (*rv3560c*), *fadE31* (*rv3562*), *fadE32* (*rv3563*) and *echA13* (*rv1935c*) found in *M. tuberculosis* H37Rv (Cole *et al.* (1998) *Nature* 393: 537-544).

Genes involved in HIL metabolism are involved in inhibitor formation

To investigate whether the inhibitor is formed through metabolism of HIL, we subsequently constructed several mutants of strain RG8-37. Unmarked gene deletions of *fadE31*, *echA13* and *fadD3* were constructed in *R. erythropolis* RG8-37 using the plasmids pAR1812, pAR1816 and pAR1817, respectively, resulting in mutant strains RG45, RG46 and RG47, respectively. In addition, an *ipdF* gene deletion strain of strain RG8-37 was constructed as described previously (co-pending International Patent application PCT/EP2008/060844, filed 19 August 2008), designated strain RG48. Finally, a *fadE30* gene disruption was made by introducing pAR1818 into strain RG8-37, yielding strain RG8-37/pAR1818.

These mutants and parent strain RG8-37 were tested for growth on MM glucose agar medium with and without the addition of HIL 100 (mg/L). All strains grew well on MM glucose medium. Interestingly, growth was also observed with strains RG47, RG48 and RG8-37/pAR1818, whereas growth of strains RG45 and RG46 was still inhibited by the presence of HIL (Fig. 1). These results indicate that *fadD3*, *fadE30*, and *ipdF*, but not *fadE31* and *echA13*, are involved in the HIL dependent formation of the growth inhibitor. The results further clearly show that not HIL, but a metabolite of HIL is responsible for growth inhibition in an *ipdAB* mutant genetic background.

Identification of other genes involved in inhibitor formation by random transposon mutagenesis

In order to identify additional genes involved in inhibitor formation, transposon mutagenesis of strain RG8-37 was performed using plasmid pKGT452C β (Gartemann and Eichenlaub (2001) *J. Bacteriol.* 183: 3729-3736). The latter was introduced into RG8-37 by electroporation as previously described (Van der Geize *et al.* (2000) *Appl Environ Microbiol* 66: 2029-2036). Electroporated cells were plated onto LBP agar medium containing chloramphenicol (40 mg/l) and incubated for 3 days at 30°C. Colonies appearing were replica plated onto glucose mineral agar plates supplemented with HIL (100 mg/l) to select for transposon mutants in which inhibition by HIL was eliminated. Four mutants were obtained that were able to grow on glucose in the presence of HIL.

Chromosomal DNA of these mutants was isolated (Van der Geize *et al.* (2000) *Appl Environ Microbiol* 66: 2029-2036) and analyzed by PCR for the presence of *cmx*

(chloramphenicol resistance gene) and *bla* (ampicillin resistance gene) of pKGT452C β . PCR analysis revealed that three out of the four mutants contained both *bla* and *cmx*, indicating that genuine transposition had not occurred. Likely, random integration by illegitimate recombination had occurred as reported previously for *Rhodococcus* (Desomer *et al.* (1991) *Mol. Microbiol.* 5:2115-2124). Further analysis revealed that in several transposon mutants chromosomal deletions or rearrangements had occurred which were not further analyzed. One transposon mutant (strain RG8-37B1) was shown to have resulted from the integration of pKGT452C β into a single gene. The gene disrupted by pKGT452C β was identified as follows. Chromosomal DNA of strain RG8-37B1 was isolated and self-ligated following *Xho*I digestion. The resulting ligation mixture was used to transform *E. coli* DH5 α and transformants were selected using chloramphenicol (40 mg/l). An *Xho*I restriction site does not occur in plasmid pKGT452C β . Therefore, all *E. coli* DH5 α transformants obtained arose from the presence of pKGT452C β with additional flanking rhodococcal gene sequences of the gene disruption site. Nucleotide sequence analysis of the plasmid isolated from these *E. coli* DH5 α transformants revealed that a rhodococcal orthologue of *rv3559* of *M. tuberculosis* had been inactivated by pKGT452C β insertion. Interestingly, *rv3559* in *M. tuberculosis* is located next and downstream of *fadE30* in the *M. tuberculosis* H37Rv genome. As describe above, *fadE30* had already been identified as involved in HIL metabolism and inhibitor formation. Thus, the Rv3559 orthologue in *R. erythropolis* RG8-37 is yet another gene involved in HIL metabolism and inhibitor formation.

Inactivation of ipdAB in M. smegmatis mc²155 blocks growth on HIL

Bioinformatic analysis revealed that all identified genes of *R. erythropolis* involved in HIL metabolism were conserved in *M. tuberculosis* H37Rv. To investigate whether inhibition by HIL in an *ipdAB* genetic background also occurs in mycobacteria, we constructed an *ipdAB* mutant of *Mycobacterium smegmatis* mc²155. Unlike *M. tuberculosis*, *M. smegmatis* is a fast growing mycobacterial species. Therefore, *M. smegmatis* is often used as a model organism to study and predict the metabolism of *M. tuberculosis*.

The *ipdA* and *ipdB* genes of *M. smegmatis* mc²155 were identified by homology searches and were found to correspond to genes designated MSMEG_6002 and MSMEG_6003, respectively. For the unmarked gene deletion of the *ipdAB* genes in *M. smegmatis* mc²155, plasmid pK18-ipdABsmeg was constructed as follows. The

upstream (forward primer 5' TTCGAGATGGCCGCGATCGAAT and reverse primer 5' ACTAGTGATGGTCATGCCGCTCTCGATA) and downstream (forward primer 5' ACTAGTCAGGTCGCCGACAACACCTCGT and reverse primer 5' AAGCTTGAATTCTGTCGCCGACGGTGAAG) flanking regions of the *ipdAB* genes were amplified by PCR using genomic DNA of *M. smegmatis* mc²155 as template. The obtained amplicons were ligated into *Sma*I digested pK18mobsacB (Schäfer *et al.* (1994) *Gene* 145:69-73), resulting in pK18-*ipdABsmegUP* and pK18-*ipdABsmegDOWN*, respectively. A 1.5 kb DNA fragment obtained from *Bam*HI/*Spe*I digested pK18-*ipdABsmegUP* was subsequently ligated into pK18-*ipdABsmegUP* linearized with *Bam*HI/*Spe*I, resulting in the construction of pK18-*ipdABsmeg* used for *ipdAB* gene deletion. An unmarked *ipdAB* gene deletion mutant of *M. smegmatis* mc²155 was constructed using the *sacB* counter selection system (Pelicic *et al.* (1996) *Mol Microbiol* 20: 919-925) as follows.

M. smegmatis Δ *ipdAB* and wild type strain mc²155 were subsequently plated onto mineral agar plates supplemented with HIL (500 mg/l) and incubated at 37°C. Contrary to the wild type strain, the Δ *ipdAB* mutant strain was unable to grow on MM-HIL agar plates, indicating that the *ipdAB* genes of *M. smegmatis* are essential for growth on HIL as sole carbon and energy source and indicating that the *ipdAB* genes have a similar function in mycobacteria and rhodococci.

Cell growth inhibition of *M. smegmatis* Δ *ipdAB* by addition of HIL

To study the effect of HIL on cell growth of *M. smegmatis* Δ *ipdAB*, the *ipdAB* mutant was grown in TSB supplemented with 0.05% Tween80 and grown for 2 days. The pre-culture was used to inoculate (1:500) mineral glucose medium containing 100 and 200 mg/l HIL. Growth inhibition was observed in both cases. Contrary to *R. erythropolis* RG8-37, addition of HIL did not fully block growth, but delayed the onset of growth for approximately 48 hours.

The inhibition screening was also performed on glucose mineral agar plates containing HIL (200 mg/l). Cell pre-cultures of wild type strain and Δ *ipdAB* mutant strain were plated out and incubated for several days at 37°C. After 3 days of growth, wild type agar plates were confluent, whereas no growth appeared with the *ipdAB* mutant strain. Further incubation of the mutant resulted in the appearance of a small number of spontaneous resistant colonies. Apparently, over time, resistance of *ipdAB*

mutant cells towards HIL had developed, providing an explanation for the delayed growth of this mutant observed in glucose liquid medium supplemented with HIL.

The results indicate that an inhibitor of cell growth is synthesized in the presence of HIL both in *Rhodococcus* and *Mycobacterium* species in an *ipdAB* genetic background.

5

Identification of HIL derivatives with inhibitory activity towards wild type *Rhodococcus*

The observed growth inhibition induced in the presence of HIL does not occur with *R. erythropolis* SQ1 wild type strain. Several derivatives of HIL, harboring the 7a-methyloctahydroinden structure with different substituents, were therefore tested to screen for compounds capable of growth inhibition of wild type *R. erythropolis* SQ1 on mineral glucose agar plates containing 0.01% (w/v or v/v, depending whether the test compound was solid or liquid) of the test compound (Fig.2). Growth inhibition of *R. erythropolis* SQ1 occurred only with compound I, racemic compound II and compound III. Racemic compound II showed the strongest inhibition of growth. Growth inhibition by compound I, racemic compound II and compound III was even more pronounced in mutant strain RG8-37. Thus, the *ipdAB* genes appear to play a role in the inhibitory effects observed when incubating cells with compound I, racemic compound II and compound III. Bioconversion of AD (0.5 g/L) with cell cultures of strain RG8-37 grown in mineral glucose medium revealed that, contrary to HIL, 3-ketosteroid 9 α -hydroxylase activity was not inhibited by racemic compound I and racemic compound II. AD was converted into 9OHAD with yields of up to 90% within 8 hours comparable to controls where no test compound was added. These results suggest that different growth inhibitory metabolites may be formed from compounds containing the 7a-methyloctahydroinden structure.

25

Compound II and compound III inhibit growth of rhodococci and mycobacteria

The growth inhibitory activity of racemic compound II and compound III were also tested in glucose mineral liquid cultures of wild type *R. erythropolis* SQ1 and wild type *M. smegmatis* mc²155 (Fig. 3A and B). The addition of 0.01% racemic compound II or 0.01% compound III to such cultures was shown to have a strong inhibitory effect on the growth of *R. erythropolis* SQ1. The growth of *M. smegmatis* mc²155 was also inhibited by these compounds, but to a much lesser extent, indicating differences in


30

metabolism of these test compounds by *R. erythropolis* SQ1 compared to *M. smegmatis* mc²155.


The separate enantiomers of compound II were tested in glucose mineral liquid cultures of *R. erythropolis* SQ1. The addition of 0.01% of (-)-compound II did not inhibit the growth of wild type strain SQ1, although a lower growth yield was obtained (Fig. 3A).
5 The addition of 0.01% of (+)-compound II to cell cultures of wild type strain SQ1 inhibited growth comparable to racemic compound II (Fig. 3). The (+)-(1S, 3aR, 7aS)-enantiomer is the active constituent of racemic compound II.

CLAIMS


1. A pharmaceutical composition for use in the treatment of a disease caused by a bacterium that belongs to the group of nocardioform actinomycetes, said composition comprising an effective amount of a compound selected from compound I, (+)-compound II, (-)-compound II, compound III, or mixtures thereof:




Compound I



(+) -Compound II




(-) -Compound II




Compound III

2. The composition of claim 1 comprising an effective amount of (+)-compound II:




(+) -Compound II


3. The composition of claims 1 or 2 comprising in addition one or more pharmaceutical carriers.
- 5 4. The composition of any one of the preceding claims for use in the treatment of a disease caused by a bacterium of one of the family Mycobacteriaceae, Nocardiaceae and Corynebacteriaceae.
- 10 5. The composition of claim 4 for use in the treatment of a disease caused by a bacterium of one of the genera *Mycobacterium*, *Nocardia*, *Rhodococcus*, and *Corynebacterium*.
- 15 6. The composition of claim 5 for use in the treatment of a disease caused by a bacterium of one of the species *Mycobacterium tuberculosis*, *Mycobacterium ulcerans*, *Mycobacterium bovis*, *Mycobacterium avium*, *Mycobacterium avium paratuberculosis*, *Nocardia seriolae*, *Nocardia farcinia*, *Nocardia asteroides*, *Rhodococcus equi*, or *Corynebacterium pseudotuberculosis*.
- 20 7. The composition according to any one of the preceding claims for use in the treatment of diphtheria, tuberculosis in cattle, equine tuberculosis, or tuberculosis in a subject.
- 25 8. A method for treating a subject suffering from a disease caused by a bacterium which belongs to the group of nocardioform actinomycetes, said method comprising administering to the subject an effective amount of a compound selected from compound I, (+)-compound II, (-)-compound II, compound III or mixtures thereof:




Compound I



(+)-Compound II




(-)-Compound II



Compound III

9. The method according to claim 8 wherein the compound is



(+)-Compound II

5


10. The method of claims 8 and 9 wherein the disease is caused by a bacterium of one of the family Mycobacteriaceae, Nocardaceae and Corynebacteriaceae.
- 10 11. The method of claim 10 wherein the disease is caused by a bacterium of one of the genera *Mycobacterium*, *Nocardia*, *Rhodococcus*, and *Corynebacterium*.
12. The method of claim 11 wherein the disease is caused by a bacterium of one of the species *Mycobacterium tuberculosis*, *Mycobacterium ulcerans*,

Mycobacterium bovis, *Mycobacterium avium*, *Mycobacterium avium paratuberculosis*, *Nocardia seriolae*, *Nocardia farcinia*, *Nocardia asteroides*, *Rhodococcus equi*, or *Corynebacterium pseudotuberculosis*.

13. The method according to any of the preceding claims 8 to 12 wherein the disease is diphtheria, tuberculosis in cattle, equine tuberculosis, or tuberculosis in humans.

14. The method according to any of the preceding claims 8 to 13 wherein the subject is a human.

15. (+)-(1S, 3aR, 7aS)-7a-methyl-1H-octahydroinden-1-ol



(+)-Compound II




Figure 1.




Figure 2




Figure 3.

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2010/052299

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61P31/04 A61P31/06 A61K31/045 A61K31/122 A61K31/222
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data, BEILSTEIN Data, EMBASE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MUELLER, M. ET AL: "Epimerization at a quaternary C-substituted carbon atom" TETRAHEDRON, vol. 37, no. s1, 1981, pages 257-261, XP001539590 ISSN: 0563-2072 cited in the application compound 24 ----- -/--	15

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

29 April 2010

Date of mailing of the international search report

10/05/2010

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Madalinska, K

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2010/052299

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BAGGALEY K H ET AL: "Bicyclo[4.3.0]nonanes (hydrindans). 1" JOURNAL OF THE CHEMICAL SOCIETY, SECTION C, no. 15, 1 January 1971 (1971-01-01), pages 2671-2678, XP009125262 ISSN: 0022-4952 abstract right-hand column, paragraph 4 - page 2674, left-hand column, paragraph 1; compound 37	15
A	----- WO 2007/118329 A (UNIV BRITISH COLUMBIA [CA]; UNIV KINGSTON [CA]; ELTIS LINDSAY [CA]; SN) 25 October 2007 (2007-10-25) cited in the application abstract; claims 1-12; table 2; compounds 2-CL-3-HSA, 4-F-3-DHSA, 2-CL-3,4-DHSA compounds 7,7-DIHYDROXYMETHYL-3,4-DHSA -----	1-15
A	YANG, NIEN-CHU ET AL: "Photochemistry of 8-methyl-1-hydrindanones and 9-methyl-1-decalones" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 93, no. 2, 27 January 1971 (1971-01-27), pages 530-532, XP002554056 ISSN: 0002-7863 compound 1B -----	1-15
A	SIH ET AL: "Mechanisms of steroid oxidation by microorganisms" BIOCHIMICA ET BIOPHYSICA ACTA, vol. 62, no. 3, 27 August 1962 (1962-08-27), pages 541-547, XP024565445 ISSN: 0006-3002 compound XIII -----	1-15

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP2010/052299

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:
- a. (means)
- ☐ on paper
- ☒ in electronic form
- b. (time)
- ☒ in the international application as filed
- ☐ together with the international application in electronic form
- ☐ subsequently to this Authority for the purpose of search
2. ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2010/052299

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2007118329 A	25-10-2007	US 2010041631 A1	18-02-2010